Clinical trials: Revascularization
Ischemic Heart Disease, Stenotic Coronary Lesion
RESOLUTE China RCT
The primary objective of this study is to evaluate the in-stent late lumen loss (LLL) at 9 months, defined as the difference between the post-procedure minimal lumen diameter (MLD) and the follow-up angiography MLD, of the…
- Conditions
- Ischemic Heart Disease, Stenotic Coronary Lesion, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- R-China RCT (NCT01334268)
- Testing
- Taxus Liberte Paclitaxel-Eluting Coronary Stent System, Resolute Zotarolimus-Eluting Coronary Stent System
- Where
- 4 sites in China
- Volunteers
- 400 people
- Sponsor
- Medtronic Vascular
Coronary Artery Disease
Efficacy of Automated Distal Vascular Anastomosis in Coronary Surgery: Phase II
This evaluation is designed to evaluate the feasibility of using an automated distal coronary anastomotic to facilitate grafting of the left internal mammary artery to the left anterio descending coronary artery during myocardial…
- Trial name
- NCT00292500
- Testing
- Automated distal anastomotic device
- Where
- Germany
- Volunteers
- 170 people
- Sponsor
- Cardica, Inc
Peripheral Arterial Disease
Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization
This is a prospective, multi-center, pilot feasibility study to document the effects of adventitial delivery of temsirolimus or temsirolimus with dexamethasone sodium phosphate injection, USP, after revascularization of…
- Trial name
- TAP-DANCE (NCT03942601)
- Testing
- Temsirolimus, Temsirolimus and dexamethasone sodium phosphate
- Where
- 11 sites in United States
- Volunteers
- 10 people
- Sponsor
- Mercator MedSystems, Inc.
Acute Myocardial Infarction, STEMI
Evaluation in STEMI Patients Using FDY-5301
To assess the effect of FDY-5301 on cardiovascular mortality and acute heart failure events in subjects with an anterior STEMI undergoing pPCI.
- Conditions
- Acute Myocardial Infarction, STEMI, Percutaneous Coronary Revascularization
- Trial name
- IOCYTE AMI-3 (NCT04837001)
- Testing
- FDY-5301
- Where
- 52 sites in United States, Canada and 4 more
- Volunteers
- 2,351 people
- Sponsor
- Faraday Pharmaceuticals, Inc.
Carotid Atherosclerosis, Carotid Artery Disease
ACCULINK for Revascularization of Carotids in High Risk Patients "The ARCHeR Trial"
1. To evaluate the safety and efficacy of the over-the-wire (OTW) ACCULINK (tm) System in patients deemed to be either at high risk or unsuitable for carotid endarterectomy (CEA) 2.
- Trial name
- NCT00180518
- Testing
- Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system
- Volunteers
- 581 people
- Sponsor
- Abbott Medical Devices
Peripheral Artery Disease, Critical Limb Ischemia
Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee
A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of Temsirolimus Perivascular Injection 0.1 mg/mL on the incidence of ischemia-driven major amputation, clinically driven target lesion…
- Trial name
- TANGO-3 (NCT04433572)
- Testing
- Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 250 people
- Sponsor
- Mercator MedSystems, Inc.
Coronary Artery Disease
Coronary Flow Reserve Following Orbital Atherectomy
The purpose of the study was to evaluate coronary artery flow reserve (CFR) following successful percutaneous coronary intervention (PCI) treatment of severely calcified coronary lesions by orbital atherectomy and stenting.
- Trial name
- NCT02339545
- Testing
- Coronary Orbital Atherectomy plus Stenting
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Abbott Medical Devices
Cardiovascular Disease, Cerebrovascular Accident
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients…
- Conditions
- Cardiovascular Disease, Cerebrovascular Accident, Coronary Heart Disease
- Trial name
- TNT (NCT00327691)
- Testing
- Atorvastatin
- Where
- 314 sites in United States, Australia and 12 more
- Volunteers
- 8,600 people
- Sponsor
- Pfizer
Ischemic Heart Disease, Myocardial Ischemia
The Safety and Efficacy of 'AVI' Stent for Treating Coronary Revascularization
The study is a Prospective, Multi-center, Single Armed Registry to Evaluate The Safety and Efficacy of 'AVI' Stent for Treating Coronary Revascularization.
- Conditions
- Ischemic Heart Disease, Myocardial Ischemia, Coronary Disease, Acute Coronary Syndrome
- Trial name
- NCT02117843
- Testing
- AVI® Arsenic trioxide drug eluting stent
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Beijing AmsinoMed Medical Device Co., Ltd
Peripheral Artery Diseases
Detour2 Continued Access Study
Prospective, single-arm, multi-center, clinical investigation to continue to evaluate the safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant stent grafts for a percutaneous femoropopliteal…
- Trial name
- NCT04625660
- Testing
- PQ Bypass System
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Endologix
Stroke, Acute
Solitaire FR Thrombectomy for Acute Revascularisation
The objective of this study was to obtain prospective clinical data on the safety and efficacy of the Solitaire™ FR device for patients diagnosed with acute ischemic stroke.
- Trial name
- STAR (NCT01327989)
- Testing
- Solitaire™ FR device
- Where
- 2 sites in Switzerland
- Volunteers
- 202 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III All-comers Orsiro Safety and Performance Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- BIOFLOW-III (NCT01553526)
- Where
- 43 sites in Austria, Chile and 11 more
- Volunteers
- 1,356 people
- Sponsor
- Biotronik AG
Ischemic Stroke
SOLITAIRE™ FR With the Intention For Thrombectomy (SWIFT) Study
The purpose of this study is to demonstrate substantial equivalence of the SOLITAIRE™ FR Revascularization Device (SOLITAIRE™ Device) with a legally marketed device, MERCI Retrieval System® (MERCI® Device).
- Trial name
- SWIFT (NCT01054560)
- Testing
- SOLITAIRE™ Device, MERCI® Device
- Where
- 2 sites in United States
- Volunteers
- 144 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Israel Satellite Registry
BIOTRONIK - SaFety and Performance Registry for a diabetic patient population with the .bimus Eluting Orsiro Stent System Within daily clinical practice - III
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01895712
- Where
- 6 sites in Israel
- Volunteers
- 120 people
- Sponsor
- BIOTRONIK Israel
Coronary (Artery); Disease
Trial of MiStent Compared to Xience in Japan
To compare the MT005 (MiStent) with the XIENCE with respect to target lesion failure (TLF) at 12 months in a non-inferiority trial in a "real world" patient population and to confirm that the domestic extrapolation of the…
- Trial name
- DESSOLVEJ (NCT02972671)
- Testing
- MiStent (MT005) Coronary Artery Stent, Xience Coronary Artery Stent
- Where
- 10 sites in Japan
- Volunteers
- 120 people
- Sponsor
- Micell Technologies
Coronary Self Expanding Stent
Registry to Assess the STENTYS Xposition S for Revascularization of Coronary Arteries In Routine cliNical Practice
WIN is a prospective, observational multinational post-marketing registry designed to evaluate the safety and effectiveness of the XPOSITION S STENT used in routine clinical practice.
- Trial name
- WIN (NCT03115281)
- Testing
- PCI
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 750 people
- Sponsor
- Stentys
Coronary Artery Disease, Myocardial Ischemia
Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent
The purpose of this study is to evaluate the safety and feasibility of a new coronary artery stent for treating blockages in the arteries supplying blood to the heart muscle.
- Trial name
- MEND II (NCT02189499)
- Testing
- AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
- Where
- 4 sites in Colombia
- Volunteers
- 42 people
- Sponsor
- Amaranth Medical Inc.
Coronary Artery Diseases
BIOFLOW-III VIP Russia Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the patient's body…
- Trial name
- NCT02247492
- Where
- 7 sites in Russia
- Volunteers
- 200 people
- Sponsor
- Biotronik Russia
Cardiovascular Disease
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for…
- Trial name
- NCT07136012
- Testing
- Olpasiran
- Where
- 252 sites in United States, Australia and 1 more
- Volunteers
- 11,000 people
- Sponsor
- Amgen
Critical Limb Ischemia, Peripheral Vascular Disease
Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures
The purpose of this study is to assess and compare the safety of continuous and daily subcutaneous Remodulin therapy in patients with critical limb ischemia (CLI) with no planned vascular interventional procedures; and to…
- Conditions
- Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
- Trial name
- NCT00060996
- Testing
- Remodulin® (treprostinil sodium) Injection
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- United Therapeutics